|

SOX chemotherapy Clinical Trials

5 actively recruiting trials

Pipeline

Phase 2: 4Phase 3: 1

Top Sponsors

  • The First Affiliated Hospital with Nanjing Medical University2
  • Beijing Friendship Hospital2
  • Akeso1

Indications

  • Cancer5
  • Adenocarcinoma of Stomach1
  • Adenocarcinoma of GE Junction1
  • GC/GEJC1
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma1

Other5 trials

A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer
Phase 2
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Phase 3
Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer
Phase 2
Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage Ⅲ Gastric Cancer: A Prospective, Multicenter, Randomized, Phase Ⅱ Clinical Trial
Phase 2
Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.